Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
about
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementCombination therapy of statins and fibrates in the management of cardiovascular risk.A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial resultsStatin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner.Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies.AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.Diagnosis and treatment of severe hypertriglyceridemia.Targeting ApoC-III to Reduce Coronary Disease Risk.Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
P2860
Q33933474-EA33A97E-17C7-4AEC-8EB4-93E0F0C847D6Q34181381-269845A0-D02E-4E08-A95B-FC25CA13D206Q34305993-A0E55FC9-3962-4DAE-9EE0-6C54E0EDF2C4Q36011053-541BAAC6-BCD6-4A74-8F5F-235370C28ED7Q36302783-D69A54B4-5043-4935-9C56-1A6C3F1C4994Q36731776-640A1076-2791-40AA-9905-8352D0AF6F97Q37227150-A488E0C8-377D-4309-AFD0-A1CAFE261010Q37772510-F87CF5E3-8FD2-4157-B24B-E62BEB550085Q37851958-AD699E9E-8697-467B-8835-6990E5F87203Q37898699-7F256DAC-4C16-4B46-978E-32BE95778AD6Q37998115-1F068D19-66CC-4817-94EA-05AF1A2F1766Q38904497-3C821D9B-2528-4F8F-8288-7EE60885D025Q42697614-34D7551D-D348-4B25-9A34-FCF279F18CC3Q50075898-D982E7AE-C11C-4384-BBAB-B4B2DA1F683B
P2860
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Atorvastatin and fenofibrate h ...... n with the metabolic syndrome.
@en
Atorvastatin and fenofibrate h ...... n with the metabolic syndrome.
@nl
type
label
Atorvastatin and fenofibrate h ...... n with the metabolic syndrome.
@en
Atorvastatin and fenofibrate h ...... n with the metabolic syndrome.
@nl
prefLabel
Atorvastatin and fenofibrate h ...... n with the metabolic syndrome.
@en
Atorvastatin and fenofibrate h ...... n with the metabolic syndrome.
@nl
P2860
P50
P1476
Atorvastatin and fenofibrate h ...... en with the metabolic syndrome
@en
P2093
Anthony G Johnson
P2860
P304
P356
10.1161/ATVBAHA.108.170530
P407
P577
2008-06-19T00:00:00Z